Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

BDTX vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)

BDTX Overall Winner 6-Pillar Tally: BDTX 3 – 2 LYRA (1 Tie) Matrix Metrics: BDTX 8 – 1 LYRA

As of Nov 17, 2026, Black Diamond Therapeutics, Inc. (BDTX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDTX carries a Unified Composite Score of 56.1/100 (HOLD) at $1.41 (8.3x Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Technical & Structure Timing Caution: BDTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BDTX vs LYRA
BDTX NASDAQ Head-to-Head Winner
Black Diamond Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.41
-7.84% 1D
Market Cap $84.5M
TTM Revenue N/A
Forward P/E 8.3x
Beta / 30D Vol 1.80β · 111% Vol
Unified Composite Score
56.1 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 37
RSI-14: 36.6 · SMA20: $1.74 · SMA50: $1.83
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (BDTX 3 – 2 LYRA)

Columns: Metric · BDTX · LYRA
1. Valuation Multiples BDTX
Forward P/E 8.3x N/M
Trailing P/E 8.3x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale BDTX
Revenue Growth (YoY) +0.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $84.5M $2.3M
3. Profitability & Quality BDTX
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -41.1% -404.5%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$33M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $952,000 Net Debt (0.18x D/E) -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LYRA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 312.8% (55th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BDTX (8) vs LYRA (1)
Institutional Metric BDTX LYRA Criterion Row Edge
Market Capitalization
Scale
$84.5M $2.3M Larger Scale BDTX
Trailing P/E Ratio
Valuation
8.3x N/M Lower Multiple BDTX
Forward P/E Ratio
Valuation
8.3x N/M Lower Multiple BDTX
Revenue Growth (YoY)
Growth
+0.0% -87.2% Higher Growth BDTX
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin BDTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-41.1% -404.5% Higher ROE BDTX
52-Week Range Position
Momentum
1% ($1–$4) 1% ($0–$38) Stronger Trend LYRA
Beta / 30D Volatility
Risk Regime
1.80β · 111% Vol 0.33β · 248% Vol Lower Realized Risk BDTX
Unified Institutional Score
Composite Signal
56.1 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite BDTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$33M ($952,000 Net Debt (0.18x D/E)) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDTX +62.5 pp
BDTX: +0.0% · LYRA: -62.5%
3M Horizon BDTX +66.97 pp
BDTX: -20.65% · LYRA: -87.62%
6M Horizon BDTX +41.75 pp
BDTX: -45.39% · LYRA: -87.14%
1Y Horizon BDTX +41.75 pp
BDTX: -45.39% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BDTX Revenue LYRA Revenue BDTX Op. Margin LYRA Op. Margin Margin Leader
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 N/A $0M N/A -4131.0% LYRA
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 N/A $0M N/A -6280.8% LYRA
FY2025 $70M $0M 17.9% -7794.5% BDTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BDTX BREAKDOWN
125d in phase · OBV NEUTRAL
Current IV 312.8%
IV Percentile 55th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BDTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BDTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $84.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BDTX vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Black Diamond Therapeutics, Inc. (BDTX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDTX carries a Unified Composite Score of 56.1/100 (HOLD) at $1.41 (8.3x Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Technical & Structure Timing Caution: BDTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.6); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BDTX leads the Growth & Scale pillar: BDTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 5-period historical trajectory (FY2021 to FY2025), BDTX cumulative revenue shifted N/A while LYRA shifted N/A. In operating R&D and SG&A reinvestment, BDTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

BDTX screens cheaper on headline valuation multiples. BDTX trades at 8.3x Forward P/E, 8.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDTX (-41.1% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BDTX carries 312.8% implied volatility (55th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 111% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.